title: Anti-tumor Effect of Intravenous Administration of CRM197 for Triple-negative Breast Cancer Therapy.
abstract: OBJECTIVE
  Heparin-binding epidermal growth factor-like growth factor (HB-EGF), which belongs to the epidermal growth factor family, is a rational therapeutic target for triple-negative breast cancer (TNBC). This study aimed to assess the anti-tumor efficacy of intravenous (i.v.) HB-EGF-specific inhibitor (CRM197) for TNBC.
  
  
  METHODS
  NOD/SCID mice were subcutaneously injected withTNBC cells, MDA-MB-231, and, then, treated with i.v. CRM197 in either dose- or frequency-dependent manners, using an advanced cancer model and an adjuvant therapy model. Tumor volume and mouse body weight were calculated weekly. Statistical significance was assessed by the Mann-Whitney U-test.
  
  
  RESULTS
  Mice that received i.v. CRM197 showed a significant anti-tumor effect in dose- and frequency-dependent manners in both models. However, their body weight did not differ significantly among groups.
  
  
  CONCLUSIONS
  These results suggest that i.v. CRM197 is an effective treatment for TNBC.
authors.affiliation: Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan Central Research Institute for Advanced Molecular Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
authors.forename: Sung Ouk
authors.initials: SO
authors.lastname: Nam
authors.affiliation: Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan Central Research Institute for Advanced Molecular Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
authors.forename: Fusanori
authors.initials: F
authors.lastname: Yotsumoto
authors.affiliation: Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan Central Research Institute for Advanced Molecular Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
authors.forename: Kohei
authors.initials: K
authors.lastname: Miyata
authors.affiliation: Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan Central Research Institute for Advanced Molecular Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Fukagawa
authors.affiliation: Kanonji Institute, Research Foundation for Microbial Diseases of Osaka University, Kagawa, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Odawara
authors.affiliation: Kanonji Institute, Research Foundation for Microbial Diseases of Osaka University, Kagawa, Japan.
authors.forename: Sadao
authors.initials: S
authors.lastname: Manabe
authors.affiliation: Kanonji Institute, Research Foundation for Microbial Diseases of Osaka University, Kagawa, Japan.
authors.forename: Toyokazu
authors.initials: T
authors.lastname: Ishikawa
authors.affiliation: Department of Biochemistry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
authors.forename: Masahide
authors.initials: M
authors.lastname: Kuroki
authors.affiliation: Department of Biochemistry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
authors.forename: Shin'ichiro
authors.initials: S
authors.lastname: Yasunaga
authors.affiliation: Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan Central Research Institute for Advanced Molecular Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan smiya@cis.fukuoka-u.ac.jp.
authors.forename: Shingo
authors.initials: S
authors.lastname: Miyamoto
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001426:Bacterial Proteins / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D047368:Tumor Burden; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D001426:Bacterial Proteins; C028581:CRM197 (non-toxic variant of diphtheria toxin)
keywords: CRM197; HB-EGF; triple-negative breast cancer